Preoperative bisphosphonates in total hip arthroplasty
Preoperative use of BP ≥ six months before THA does not increase the risk of PPF and revision, and may even lower such risk, supporting safety regardless of treatment duration. Patient-related factors, such as comorbidities and hip fracture, rather than BP use itself, was a key risk factor for periprosthetic complications after THA.
Authors
- Seung Beom Han (ORCID: https://orcid.org/0000-0002-1299-2137)
- Yan Yu (ORCID: https://orcid.org/0000-0003-1120-7552)
- Seok Ha Hong (ORCID: https://orcid.org/0009-0003-3114-6045)
Institutions
- Korea University (KR)
- Korea University Medical Center (KR)
- Korea University (JP)
Publication Details
- Journal
- The Bone & Joint Journal
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1302/0301-620x.107b12.bjj-2025-0280.r1
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00